Dr. Collin Bantle

Collin partners with Sable Bio as a US Scientific Advisor, bringing deep expertise in preclinical toxicology and translational safety across biotechnology and AI-driven drug discovery organisations.

With experience spanning small molecules, radiopharmaceuticals, and cell and gene therapies, Collin has supported programmes from target evaluation through IND-enabling development, helping organisations integrate artificial intelligence into decision-making across the drug discovery and development pipeline.

Collin holds a Ph.D. in Toxicology. His expertise spans toxicology, translational science, drug development strategy, and the application of AI to improve safety assessment, accelerate development timelines, and advance the translation of innovative therapies to patients.